Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US

Amyloid toxicity induced by oligomeric Aβ25-35 injection is enhanced after pharmacologic or genetic invalidation of the σ1 chaperone protein

PIPELINEBy alessandroJanuary 11, 2013Leave a comment

Endogenous Neuroprotection in Neurodegenerative Diseases, University of Montpellier 2, Inserm U. 710, Montpellier 34095, France. (2013) Tangui Maurice, Fanny Duhr, Alisson Dekeuwer, Nathalie Chevallier. View Poster

Implication of the σ1 chaperone protein in adult neurogenesis: Contribution to neuroprotection?

PIPELINEBy alessandroJanuary 11, 2013Leave a comment

Endogenous Neuroprotection in Neurodegenerative Diseases, University of Montpellier 2, Inserm U. 710, Montpellier 34095, France. (2013) Nathalie Chevallier, Alisson Dekeuwer, Amandine Falco, Tangui Maurice. View Poster

Anavex Appoints Tom Skarpelos as Director

News ReleasesBy alessandroJanuary 10, 2013Leave a comment

Vancouver, BC — January 10, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) announces the appointment of Athanasios (Tom) Skarpelos as a Director of the company effective January 9, 2013. “Tom has been actively involved in Anavex since the very beginning,” said Sean Lowry, former Director of Anavex. “His passion for Anavex and its assets,…

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top